YMC026 + Placebo

ApprovedCompleted
0 watching 0 views this week๐Ÿ”ฅ Hot
85
Hype Score

Development Stage

โœ“
Pre-clinical
โœ“
Phase 1
โœ“
Phase 2
โœ“
Phase 3
5
Approved
Indication / Disease

Respiratory Disease

Conditions

Respiratory Disease

Trial Timeline

Oct 27, 2017 โ†’ Oct 30, 2018

About YMC026 + Placebo

YMC026 + Placebo is a approved stage product being developed by Yuhan for Respiratory Disease. The current trial status is completed. This product is registered under clinical trial identifier NCT03334916. Target conditions include Respiratory Disease.

Hype Score Breakdown

Clinical
30
Activity
20
Company
10
Novelty
10
Community
12

Clinical Trials (1)

NCT IDPhaseStatus
NCT03334916ApprovedCompleted

Competing Products

20 competing products in Respiratory Disease

See all competitors
ProductCompanyStageHype Score
Zopapogene imadenovec (Zopa)PrecigenApproved
80
PRGN-2012 - Phase I; Dose Level 1 + PRGN-2012 - Phase I; Dose Level 2 + PRGN-2012 - Phase II; Dose Level 2PrecigenPhase 1/2
36
agenT-797MiNK TherapeuticsPhase 1
25
VN-0200 + PlaceboDaiichi SankyoPhase 1
33
VN-0200Daiichi SankyoPhase 2
52
Isavuconazonium Injection [Cresemba] + PlaceboAstellas PharmaPhase 3
77
S-337395 + PlaceboShionogiPhase 2
52
SivelestatEli LillyPhase 1/2
41
Itolizumab IV infusion + Best supportive care (BSC)BioconPhase 2
52
Paracetamol 500 mg/Phenylephrine 5 mg tablets + Paracetamol 1000 mg/Phenylephrine 10 mg sachetJohnson & JohnsonPhase 1
33
Mesenchymal stem cellRohto PharmaceuticalPhase 1
33
PalivizumabAbbViePhase 3
77
PalivizumabAbbViePhase 3
77
Placebo + AZD5634AstraZenecaPhase 1
33
MEDI8897 + PalivizumabAstraZenecaPhase 2/3
65
Selumetinib + DurvalumabAstraZenecaPhase 2
52
Tozorakimab + PlaceboAstraZenecaPhase 3
77
NirsevimabAstraZenecaPhase 3
77
Nirsevimab + PlaceboAstraZenecaPhase 3
77
MEDI8897 + PlaceboAstraZenecaPhase 3
77